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Abstract
Background: The Dishevelled (Dvl) and Dishevelled-associated activator of morphogenesis 1 (Daam1) pathway triggered by
Wnt5a regulates cellular polarity during development and tissue homoeostasis. However, Wnt5a signaling in breast cancer
progression remains poorly defined.
Methodology/Principal Findings: We showed here that Wnt5a activated Dvl2, Daam1 and RhoA, and promoted migration
of breast cancer cells, which was, however, abolished by Secreted Frizzled-related protein 2 (sFRP2) pretreatment. Dominant
negative Dvl2 mutants or Dvl2 siRNA significantly decreased Wnt5a-induced Daam1/RhoA activation and cell migration.
Ectopic expression of N-Daam1, a dominant negative mutant, or Daam1 siRNA remarkably inhibited Wnt5a-induced RhoA
activation, stress fiber formation and cell migration. Ectopic expression of dominant negative RhoA (N19) or C3 exoenzyme
transferase, a Rho inhibitor, decreased Wnt5a-induced stress fiber formation and cell migration.
Conclusions/Significance: Taken together, we demonstrated for the first time that Wnt5a promotes breast cancer cell
migration via Dvl2/Daam1/RhoA.
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Introduction
Despite advances in the early diagnosis and adjuvant treatment
of breast carcinoma, this disease still remains the most common
malignancy of women worldwide [1,2]. Several improvements in
understanding the molecular pathology of metastatic breast cancer
have been achieved over the past decade. However, the molecular
mechanisms underlying this malignancy are still largely unknown.
For this reason, elucidating the signaling pathways involved in the
metastatic cascade is a key goal for developing novel effective
therapeutics aimed at reducing cancer mortality rates.
The Wnt signaling has historically been divided into two classes:
the canonical (b-catenin dependent) and non-canonical (b-catenin
independent) signaling pathway. The canonical Wnt signaling
pathway has been implicated in promoting malignant transfor-
mation and tumor progression [3,4]. Wnt/TCF signaling
program, for example, has been reported to be capable of
enhancing the competence of lung adenocarcinoma cells to
colonize the bones and the brain [5], while very limited studies
have been done on the role and mechanisms of non-canonical
Wnt signaling in tumor progression. Wnt5a is a representative of
Wnt proteins that activates non-canonical Wnt signaling. The
Wnt/planar cell polarity (PCP) pathway triggered by Wnt5a
activates small Rho-GTPases and regulates the cytoskeletal
architecture and cellular polarity during development and tissue
homoeostasis [6,7,8]. Wnt5a is classified as a non-transforming
Wnt family member that plays complicated roles in oncogenesis
and cancer metastasis. In malignant melanoma and gastric cancer,
Wnt5a actually promotes cancer progression [9,10,11]. Converse-
ly, Wnt5a functions as a tumor suppressor in colon, thyroid, and
hepatocellular cancers [12,13,14]. In the breast, dysregulated Wnt
signaling appears to occur by autocrine mechanisms [15,16,17].
Interference with autocrine Wnt signaling can block in vitro
proliferation of many human breast cancer cell lines [16,17]. The
non-transforming Wnt5a can inhibit breast epithelial cell migra-
tion [18] and predicts longer disease-free survival for patients with
breast cancer [19]. In contrast to the hypothesis that Wnt5a
functions as a tumor suppressor, Wnt5a secreted by macrophages
is proved to be essential for macrophage-induced invasiveness of
breast cancer cells [20].
These promiscuous viewpoints of Wnt5a in breast cancer
progression led us to further elucidate the function of Wnt5a, and
investigate the underlying mechanisms whereby cell migration is
regulated. Here, we demonstrated for the first time that Wnt5a
promotes the migration of breast cancer cells, and we report on
the mechanisms whereby Wnt5a/PCP signaling regulates cell
migration. Wnt5a signaling directly activates RhoA, which
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of morphogenesis 1 (Daam1).
Materials and Methods
Plasmids and transient transfections
The plasmids pCB6-GFP-RhoA-WT, V14 and N19 were kindly
provided by Dr. Ste ´phane ORY (Institute of Cellular and
Integrative Neurosciences, University of Strasbourg, France). Dr.
Marc Fiedler (MRC Laboratory of Molecular Biology, Cam-
bridge, UK) generously provided the construct of human full-
length Dvl2. The human full-length Daam1 was kindly gifted from
Dr. Raymond Habas (Departments of Biochemistry and Pharma-
cology and Cancer Institute of New Jersey, USA). Mutant
fragments of Dvl2 and Daam1 were generated by restriction
digestion or a PCR approach and subcloned in pEGFP-N1 or
pCS2 vectors. Details of plasmids are available upon request.
MDA-MB-231 and MCF-7 cell lines (ATCC, Manassas, VA)
were grown in Dulbecco’s modified Eagle’s medium (DMEM,
high glucose) (Hyclone, Thermo Scientific, Waltham, MA)
supplemented with 10% (v/v) fetal bovine serum (FBS) (Hyclone)
in a humidified incubator at 37uC with 5% CO2. The cells were
seeded in 6-well plates (Costar, Corning, NY) and cultured to
80,90% confluence, and then transiently transfected with
plasmids using Lipofectamine 2000 Reagent (Invitrogen, Carls-
bad, CA) in serum-free OPTI-MEM according to the manufac-
turer’s instructions. The cells were switched to fresh medium
containing 10% FBS 6 h after the transfection and cultured for
48 h. The cells transfected with Dvl2, Daam1 and RhoA
constructs were used for analyzing the expression of these proteins
and cell migration.
Wound-healing assay
MDA-MB-231 cells were plated onto 96-well cell culture
clusters (Costar) and grown to confluence, and then serum-starved
for 24 h. Recombinant sFRP2 (R&D Systems, Minneapolis, MN)
and C3 exoenzyme (Enzo Life Sciences, Plymouth Meeting, PA)
were used 60 min before the scratch was made. The cells
transfected with indicated plasmids were switched to fresh medium
containing 10% FBS 6 h after the transfection and cultured for
48 h, and then serum-starved for 24 h. The monolayer cells were
scratched manually with a plastic pipette tip, and after two washes
with PBS, the wounded cellular monolayer was allowed to heal for
4 h in DMEM containing 500 ng/mL recombinant Wnt5a
(rWnt5a) (R&D Systems). Photographs of central wound edges
per condition were taken at time 0 and at the indicated time points
using PowerShot G10 camera (Canon, Tokyo, Japan).
Cell migration assays
Cell migration was assessed in a modified Boyden chamber
(Costar), in which the two chambers were separated by a
polycarbonate membrane (pore diameter, 8.0 mm). Boyden
chamber wells were coated with human collagen I (20 mg/mL)
for 1 h at 37uC. MDA-MB-231 or MCF-7 cells were grown to
subconfluence in tissue culture plates and then detached, after
which they were centrifuged and rendered into single cell
suspensions in serum-free culture medium supplemented with
5 mg/mL BSA. The suspensions containing 5610
4 cells were
added to wells with a membrane placed in the bottom. For MDA-
MB-231 cell migration, medium containing 500 ng/mL rWnt5a
was added to the upper and lower compartment of the Boyden
chamber. For MCF-7 cell migration, serum-free medium was
added to the upper and lower compartment of the Boyden
chamber. The cells were allowed to migrate for the indicated
periods of time at 37uC in this assay. Thereafter, the medium was
discarded, stationary cells were removed with a cotton-tipped
applicator and the membranes were cut out of the chamber and
stained with 0.5% crystal violet. The response was evaluated in a
light microscope by counting the number of cells that had
migrated into the membrane.
RNAi
For gene knockdown, small interfering RNA (siRNA) duplexes
specific for Dvl2 (On-Target Plus: 59-GUGAGAGCUACCUA-
GUCAATT-39 and 59-CGCUAAACAUGGAGAAGUATT-39;
GenePharma, Shanghai, China; GenBank/EMBL/DDBJ acces-
sion No. NM_004422), and Daam1 (On-Target Plus: 59-GCU-
GUAUAAAGGCGUUAAUTT-39 and 59-GAGCUCA-
GAAUUGCAACAUTT-39; GenePharma; GenBank/EMBL/
DDBJ accession No. NM_014992) were transfected into MDA-
MB-231 cells using Lipofectamine 2000 Reagent as described in
the previous section. Knockdown efficiency was evaluated 48 h
after transfection by measuring mRNA and protein levels in cell
lysates using RT-PCR or immunoblotting.
Immunoblotting analysis
Subconfluent cells were washed twice with PBS, and then lysed
with ice-cold RIPA lysis buffer (50 mmol/L Tris, 150 mmol/L
NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS,
1 mmol/L sodium orthovanadate, 1 mmol/L sodium fluoride,
1 mmol/L EDTA, 1 mmol/L PMSF, and 1% cocktail of protease
inhibitors) (pH7.4). The lysates were then clarified by centrifuga-
tion at 12,000 g for 20 min at 4uC. The whole cell and nucleonic
fractions were prepared using Nuclear and Cytoplasmic Protein
Extraction Kit (Beyotime, Nantong, China). The protein extracts
were separated by 8, 10, or 12% SDS-PAGE. The immunoblot-
ting procedure was performed as described [21] and the following
antibodies were used: anti-GAPDH, b-actin (Sigma, St. Louis,
MO), Dvl2, Daam1 (Santa Cruz Biotechnology, Santa Cruz, CA),
Wnt5a (Cell Signaling Technology, Danvers, MA), RhoA (Abcam,
Cambridge, MA) and b-catenin (Bioworld Technology, St. Louis
Park, MN) antibodies. Protein bands were detected by incubation
with horseradish peroxidase-conjugated antibodies and visualized
with ECL reagent (Thermo Scientific, Rockford, IL).
Determination of Dvl2 phosphorylation status
Equal volumes of total cellular protein of MDA-MB-231 cells
were treated with phosphatase (Beyotime), phosphatase and
phosphatase inhibitor (50 mmol/L EDTA) at 37uC for 1 h. Then,
these samples were analyzed by blotting with anti-Dvl2 antibody.
Total cellular proteins were incubated with anti-Dvl2 and protein
A/G-agarose beads (Pierce, Rockfrod, IL) at 4uC for 24 h, and
then were analyzed by blotting with anti-phosphotyrosine, anti-
phosphoserine, anti-phosphothreonine antibodies (Millipore).
Pulldown assays
For detection of active RhoA, equal volumes of total cellular
protein were incubated with GST-RBD (gifted from Dr. Keith
Burridge, Department of Cell and Developmental Biology,
University of North Carolina, Chapel Hill, NC) beads captured
on MagneGST Glutathione Particles (Promega, Madison, WI) at
4uC with constant rotation for 90 min. The beads were washed
three times with washing buffer (4.2 mmol/L Na2HPO4, 2 mmol/
LK H 2PO4, 280 mmol/L NaCl, and 10 mmol/L KCl, pH7.2). At
the end of this period, beads were captured by the magnet in a
magnetic stand. After washing three times with ice-cold buffer,
beads were resuspended in Laemmli buffer, boiled, and subjected
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were performed using standard methods. For detection of active
Daam1, GST-RhoA beads were incubated with 0.1 mmol/L
GTPcS (Sigma) at 30uC for 15 min with constant agitation. The
other procedures were described as above.
Reverse transcription PCR (RT-PCR)
Total RNAs were isolated with TRIzol reagent (Invitrogen).
First-strand cDNAs were synthesized using total RNAs, avian
myeloblastosis virus (AMV) reverse transcriptase (Promega), and
an oligo(dT) primer. Primers used for PCR amplification were as
follows: GAPDH: 59-TGAACGGGAAGCTCACTGG-39 (sense)
and 59-TCCACCACCCTGTTGCTGTA-39 (antisense); Wnt5a:
59-CTTCGCCCAGGTTGTAATTGAAGC-39 (sense) and 59-
CTGCCAAAAACAGAGGTGTTATCC-39 (antisense); Dvl2: 59-
CATCCTTCCACCCTAATGTGTCC-39 (sense) and 59-GTC
CCCCAGGCTGGTACTCT-39 (antisense); Daam1: 59-AAATT-
GAAACGGAATCGCAAAC-39 (sense) and 59-GCAAGGCAG
TGTAATGAAACG-39 (antisense). RT-PCR was done for 26
cycles with each cycle for 30 sec at 94uC, 40 sec at 58uC, and
40 sec at 72uC. The PCR products were resolved by electropho-
resis on 1% agarose gel. Images of electrophoresis were taken
using the ChemiDOC XRS Imaging system (BIO-RAD Labora-
tories, Hercules, CA).
Actin cytoskeleton staining and immunofluorescence
Transfected cells were fixed in 4% paraformaldehyde in PBS for
20 min, permeabilized in 0.2% Triton X-100 and blocked in PBS
containing 1% BSA for 1 h at room temperature. F-actin was
stained with FITC-labeled phalloidin (5 mg/mL) (Sigma) for
40 min at room temperature. After wash with PBS, the cover
slips were mounted on glass slides with DAPI Fluoromount G
(Southern Biotech, Birmingham, AL). The images were acquired
with a fluorescence microscope (Olympus, Tokyo, Japan). For
semi-quantification of actin fibers, a baseline of ten actin fibers/
cell was used. Cells containing more or fewer than ten fibers were
scored as an increase or decrease, respectively.
MTT assays
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay was used for the assessment of cell proliferation.
MDA-MB-231 cells were seeded on 96-well plates in 100 mL
medium for each well, cultured at 37uC for 24 h, and then were
made quiescent by serum starvation for 24 h. Then, the cells were
cultured for 24 to 48 h. Before each time point, 20 mL MTT
solution was added to each well followed by incubation at 37uC for
4 h. After removal of the medium, 150 mL dimethylsulfoxide
(DMSO) was added to each well. After gentle shaking, absorbance
at 490 nm was measured.
Statistical analysis
The data were analyzed using Student’s t-test by SPSS statistical
software package. All the results were expressed as mean 6 s.d.
For all analyses a two-sided P value of less than 0.05 was deemed
statistically significant.
Results
Wnt5a stimulates breast cancer cell migration in vitro
To assess the effect of Wnt5a on breast cancer cell migration, we
treated MDA-MB-231 cells with different doses of recombinant
Wnt5a (rWnt5a), and measured the migration rate by wound
healing assay. MDA-MB-231 cells expressed lower levels of Wnt5a
than breast cancer cell line MCF-7 (Fig. S1), which is consistent
with the previous report [22]. The rWnt5a activity was analyzed
by immunoblotting to exclude that this recombinant protein has
not been deglycosylated (Fig. S2). We found that Wnt5a had a
potent stimulatory effect on MDA-MB-231 cell migration (Fig. 1A).
An approximately 2-fold increase in cell migration was observed in
cells treated with 500 ng/mL rWnt5a (Fig. 1A and Fig. S3). By
using Boyden chamber assay, we found that more MDA-MB-231
cells incubated with rWnt5a migrated through the membrane than
the untreated cells (Fig. 1B). We next determined whether Wnt5a
promoted the proliferation of MDA-MB-231 cells by MTT assays.
Treatment of MDA-MB-231 cells with 500 ng/mL rWnt5a
resulted in an insignificant promotion of cell growth (Fig. S4).
Accordingly, 500 ng/mL rWnt5a was used for further studies to
identify the mechanism whereby changes in the migration of
MDA-MB-231 cells were induced.
Pre-incubation of Secreted Frizzled-related protein 2 (sFRP2),
an antagonist that directly binds to Wnts [23], abolished rWnt5a
(500 ng/mL)-stimulated MDA-MB-231 cell migration (Fig. 1C).
SFRP2 does not alter the nuclear translocation of b-catenin in
MDA-MB-231 cells (Fig. S5). Additionally, low dose of sFRP2
abolished MCF-7 cell migration (Fig. 1D). Taken together, these
experiments demonstrated that Wnt5a stimulated MDA-MB-231
and MCF-7 cell migration in vitro.
Dvl2 activation is required for Wnt5a-induced cell
migration
In view of the fact that several Wnt proteins, such as Wnt5a,
trigger Dvl2 phosphorylation in other cell types [24,25], we
speculated that Wnt5a may also promote Dvl2 phosphorylation in
MDA-MB-231 cells. To confirm that the upper band correspond-
ed to a more highly phosphorylated form of Dvl2, extracts of
MDA-MB-231 cells were treated with phosphatase in the presence
or absence of phosphatase inhibitors (Fig. S6). As expected, the
shifted band of Dvl2 was the phosphorylated form (Fig. S6).
Afterwards, Dvl2 showed visible signs of basal phosphorylation
and elevated phosphorylation at 1 min after treatment with
500 ng/mL rWnt5a (Fig. 2A). Maximal phosphorylation was
detected at 5 min after treatment (Fig. 2A). Pre-treatment with
1000 ng/mL sFRP2 blocked Wnt5a-induced Dvl2 phosphoryla-
tion (Fig. 2B), indicating that the effects observed were specifically
induced by Wnt5a.
We next sought to determine whether Dvl2 activation was
required for Wnt5a-mediated MDA-MB-231 cell migration. Dvl2
has three major functional domains: the DIX domain, the central
PDZ domain, and the C-terminal DEP domain (Fig. 2C). The
DIX domain is essential for b-catenin signaling but dispensable for
PCP, whereas both the PDZ and DEP domains are required for
PCP function [26,27,28,29,30]. We created a panel of Dvl2
mutants (Fig. 2C) and tested their roles in cell migration (Fig. 2E).
The puncta of wild-type (WT) Dvl2 or mutants tagged with
enhanced green fluorescent protein (EGFP) were transiently
transfected into MDA-MB-231 cells (Fig. 2D). The expression
efficiency of EGFP-tagged puncta was 60,70% as observed under
a fluorescence microscope. DPDZ-Dvl2 (lacking the PDZ domain)
and DDEP-Dvl2 (lacking the DEP domain) were capable of
retarding Wnt5a-induced cell migration, and the overexpression of
WT-Dvl2 was not able to accelerate cell migration (Fig. 2E). These
findings, thus, suggested a close correlation between two specific
domains of Dvl2 and MDA-MB-231 cell migration.
We also used siRNA to knock down Dvl2 expression in breast
cancer cells and checked whether Wnt5a-induced cell migration
could be inhibited. The siRNA against human Dvl2 knocked
down Dvl2 expression by more than 50% as assessed by RT-PCR
and immunoblotting in MDA-MB-231 cells (Fig. 2F), which
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(Fig. 2G). Taken together, these experiments demonstrated that
Wnt5a induced the migration of MDA-MB-231 cells by integrat-
ing the whole functional domains of Dvl2.
Daam1 acts as a downstream target of Dvl2 and
mediates Wnt5a-induced cell migration
Binding of Daam1 to Dvl and the small GTPase Rho has been
shown to coordinate Wnt signaling cues in Xenopus [31]. We
examined whether Daam1 was also activated by Wnt5a in MDA-
MB-231 cells. Immunoblotting showed a visible sign of basal active
Daam1 and a clear maximal effect after 30 min of rWnt5a
treatment (Fig. 3A). We next examined whether Daam1 was the
downstream target of Dvl2 in MDA-MB-231 cells. These Dvl2
mutants (DPDZ-Dvl2 and DDEP-Dvl2) and siRNA blocked
Wnt5a-induced Daam1 activation (Fig. 3B), indicating that
Daam1 was a downstream target of Wnt5a/Dvl2 signaling in
MDA-MB-231 cells.
Because the C-terminal (C-Daam1), DDAD-Daam1 (lacking the
DAD domain) and N-terminal (N-Daam1) domains of Daam1
exert constitutively active and dominant negative functions on
PCP signaling, respectively (Fig. 3C) [31,32], we compared the
effects of these three mutants on cell migration. The puncta of
Daam1 mutants tagged with EGFP were transiently transfected
into MDA-MB-231 cells (Fig. 3D). The transfection efficiency of
EGFP-tagged puncta were 60,70% as observed under a
fluorescence microscope. Abundant DDAD-Daam1 or C-Daam1
Figure 1. Wnt5a promotes MDA-MB-231 and MCF-7 cell migration. (A, B) MDA-MB-231 cells were stimulated by rWnt5a at the indicated
doses for 4 h. The cell motility rate was measured by wound healing assays (A) or Boyden chamber assays (B). Magnification,6100 (A) and6200 (B).
(C) MDA-MB-231 cells were preincubated with Wnt5a inhibitor (sFRP2) for 1 h at the indicated doses, and migration in response to rWnt5a (500 ng/
mL, for 4 h) was measured by wound healing assays. (D) MCF-7 cells were preincubated with sFRP2 for 1 h at the indicated doses, and migration was
measured by Boyden chamber assays after 48 h. Results are presented as mean 6 s.d. of 5 independent experiments in (A) to (D).
doi:10.1371/journal.pone.0037823.g001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37823Figure 2. Dvl2 activation is required for Wnt5a-induced MDA-MB-231 cell migration. (A, B) Dvl2 activation was induced by Wnt5a (A) and
blocked by sFRP2 (B). Serum-starved MDA-MB-231 cell monolayers were incubated with 500 ng/mL rWnt5a for 0–60 min (A), or treated with
1000 ng/mL sFRP2 for 1 h prior to 500 ng/mL rWnt5a treatment for 5 min (B). Cell lysates were assayed for phosphorylated Dvl2 by immunoblotting
analyses with anti-Dvl2 and b-actin antibodies. Results are presented as mean 6 s.d. of 3 independent experiments in (A) and (B). (C) The domain
structures of Dvl2 and two mutants. Schematic representations of wild-type Dvl2, DPDZ-Dvl2 (lacking the PDZ domain), and DDEP-Dvl2 (lacking the
DEP domain). Residue numbers above domains denote the domain boundaries. (D) Expression of empty vector, WT-Dvl2, DPDZ-Dvl2 or DDEP-Dvl2
was verified using total protein from cells and immunoblotted using anti-GFP antibody. (E) Overexpression of DPDZ-Dvl2 and DDEP-Dvl2 in cells
abolished Wnt5a-induced cell migration. MDA-MB-231 cells transiently transfected with EGFP-tagged empty vector, WT-Dvl2, DPDZ-Dvl2 or DDEP-
Dvl2 were incubated in the absence or presence of 500 ng/mL rWnt5a. The cell migration rate was determined by wound healing assays. (F)
Efficiency of gene knockdown was analyzed by RT-PCR (left) and immunoblotting (right) for Dvl2. MDA-MB-231 cells were transfected with control
(Mock) or Dvl2 siRNAs. Total mRNA or protein extracts from MDA-MB-231 transfected with control (Mock) or Dvl2 siRNA were analyzed by RT-PCR and
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of retarding the migration of MDA-MB-231 cells (Fig. 3E). Thus,
there was a close correlation between active Daam1 and MDA-
MB-231 cell migration.
To analyze the role of endogenous Daam1 activation on
Wnt5a-induced cell migration, we knocked down Daam1 expres-
sion using siRNA. The siRNA against human Daam1 reduced the
mRNA and protein levels of Daam1 by more than 50%, as
assessed by RT-PCR and immunoblotting (Fig. 3F) and signifi-
cantly reduced Wnt5a-induced migration of MDA-MB-231 cells
(Fig. 3G). Taken together, these experiments demonstrated that
active Daam1 was the downstream target of Wnt5a/Dvl2 and its
activation was required for Wnt5a-induced MDA-MB-231 cell
migration.
Wnt5a induces cell migration via RhoA activation
We first investigated whether RhoA activation was induced by
Wnt5a in MDA-MB-231 cells. Immunoblotting showed a visible
sign of basal active RhoA and a maximal effect at 30 min after
rWnt5a treatment (Fig. 4A). We next examined whether RhoA
was downstream of Dvl2 in human breast cancer cells. Blocking
Dvl2 with dominant negative mutants (DPDZ-Dvl2 and DDEP-
Dvl2) or siRNA abolished Wnt5a-induced RhoA activation
(Fig. 4B). These results indicated that RhoA functioned directly
downstream of Dvl2 in MDA-MB-231 cells.
To study the role of RhoA activation in cell migration, we used
C3 exoenzyme transferase, a Rho inhibitor (Fig. 4C, Fig. S7). Pre-
incubation with 10 ng/mL C3 transferase for 1 h completely
inhibited rWnt5a (500 ng/mL)-induced MDA-MB-231 cell mi-
gration (Fig. 4C). To further investigate the role of RhoA in cell
migration, we transiently transfected MDA-MB-231 cells with
GFP-tagged WT-RhoA, V14-RhoA (constitutively active mutant),
or N19-RhoA (dominant negative mutant) (Fig. 4D). Overexpres-
sion of abundant WT-RhoA or V14-RhoA had no effect on cell
migration, but overexpression of N19-RhoA completely abolished
Wnt5a-induced cell migration (Fig. 4E). Thus, we concluded that
RhoA activation was involved in Wnt5a-induced MDA-MB-231
cell migration.
Dvl2-dependent RhoA activation requires Daam1 activity
Formin proteins, such as Daam1, regulate the actin dynamics
by assembling actin filaments, which is also under the control of
the Rho family GTPases [33,34]. We found that ectopic
expression of DDAD-Daam1 and C-Daam1 could induce RhoA
activation (Fig. 5A), and overexpression of N-Daam1 or knock-
down of Daam1 expression by siRNA blocked Wnt5a-induced
RhoA activation (Fig. 5A), indicating that Daam1 acted as
upstream of RhoA signaling in MDA-MB-231 cells.
To examine whether RhoA regulated Daam1 in MDA-MB-231
cells, we detected the activity of Daam1 after transiently
transfecting MDA-MB-231 cells with WT-RhoA and RhoA
mutants, respectively (Fig. 5B). There was no change in Daam1
activity after transfection in the absence or presence of Wnt5a. We
further studied the coordinating role of Daam1 and RhoA
activation in cell migration by transiently co-transfecting N19-
RhoA and DDAD-Daam1 into MDA-MB-231 cells. We found
that N19-RhoA and DDAD-Daam1 abolished Wnt5a-induced
MDA-MB-231 migration (Fig. 5C).
Then, we examined whether Daam1 could activate RhoA in
other human breast cancer cells. We transiently transfected MCF-
7 cells, which express high levels of Wnt5a (Fig. S1), with DDAD-
Daam1 (Fig. 5D) and found that DDAD-Daam1 enhanced RhoA
activation (Fig. 5E). Based on the similar pattern of Daam1 and
RhoA activation between MDA-MB-231 and MCF-7 cell lines, we
speculated that active Daam1 can induce the migration of MCF-7.
Indeed, overexpression of DDAD-Daam1 can promote MCF-7
migration (Fig. 5F). Together, these data strongly suggested that
Daam1 was required to induce RhoA activation and participated
in Wnt5a-induced MDA-MB-231 and MCF-7 migration.
Rho GTPases are key regulators of the actin cytoskeleton [35].
We performed fluorescent phalloidin staining to investigate the
distribution pattern of F-actin in MDA-MB-231 and MCF-7 cells.
We found that N-Daam1 disrupted the formation of actin stress
fibers in MDA-MB-231 cells, similar to those with C3 transferase
treatment (Fig. 6A and 6B). In contrast, DDAD-Daam1 enhanced
the formation/maintenance of actin stress fibers in MCF-7 cells
(Fig. 6C and 6D). Thus, the findings from the cell biological assay
are consistent with the biochemical evidence that RhoA activation
required Daam1 activity.
Discussion
Wnt5a is one of the most highly investigated non-canonical
Wnts and has been implicated in almost all aspects of non-
canonical Wnt signaling. Wnt5a was able to polarise the cellular
cytoskeleton of melanoma cells through a process dependent on
dishevelled, RhoB and Rab4 to promote cellular migration
towards the source of the CXCL12 chemokine [36]. The second
main Wnt5a-dependent pathway is the calcium-dependent signal-
ing pathway, which could have an oncogenic effect by stimulating
cancer cell invasion [37]. Wnt5a can also bind and activate the
ROR2 tyrosine kinase receptor resulting in the activation of the
actin-binding protein and the JNK signaling pathway [38,39]. In
addition to activating non-canonical signaling, Wnt5a is also able
to inhibit the activation of the canonical signaling pathway either
by calcium signaling through CamK II [40] or through the ROR2
signaling pathways [41]. Wnt5a has ample opportunity to
influence cancer cell signaling, resulting in functional promiscuity
on cancer development. Wnt5a actually promotes cancer
progression and metastasis, such as malignant melanoma and
gastric cancer [9,10,11]. Previous finding suggested that Wnt5a
released from tumor-associated macrophages could have a
chemotactic effect on breast cancer cells and thereby increase
metastasis [20]. However, some evidence supports the hypothesis
that Wnt5a acts as a tumor and developmental suppressor in other
breast experimental systems [18,19,42,43].
A primary observation in the present study is that Wnt5a
induces the migration of MDA-MB-231 breast cancer cells, which
lacks endogenous Wnt5a [22]. It would also be of interest to
compare the non-canonical Wnt signaling pathway in normal and
breast cancer cells. We found that, similar to the findings by other
investigators [22,44], Wnt5a expression pattern in normal breast
cells MCF-10A was similar to that in breast cancer cells (data not
shown). However, Wnt5a expression in MCF-10A cells changes in
response to in vitro growth such as in the presence of EGF,
indicating that Wnt5a signaling cannot be reliably studied in such
a model system. SFRP2 has been shown to also enhance canonical
immunoblotting for Dvl2. The same assay was performed with GAPDH as a loading standard. (G) Dvl2 siRNA significantly inhibited cell migration.
MDA-MB-231 cells transfected with control (Mock) or Dvl2 siRNA were subjected to a wound healing assay in the absence or presence of 500 ng/mL
rWnt5a. Results are presented as mean 6 s.d. of 5 independent experiments in (E) and (G).
doi:10.1371/journal.pone.0037823.g002
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37823Figure 3. Daam1 is a downstream target of Dvl2 and its activation is required for Wnt5a-induced MDA-MB-231 cell migration. (A, B)
Daam1 activation was induced by Wnt5a (A) and blocked by Dvl2 mutants or siRNA (B). Serum-starved MDA-MB-231 cell monolayers were incubated
with 500 ng/mL rWnt5a for 0–60 min (A), or transiently transfected with Dvl2 mutants or siRNA, and then incubated with 500 ng/mL rWnt5a for
30 min (B). Cellular lysates were assayed for the active Daam1 by pulldown assay using a GST-RhoA as a bait. Results are presented as mean 6 s.d. of
3 independent experiments in (A) and (B). (C) The domain structures of Daam1 and three mutants. Schematic representations of wild-type Daam1,
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37823Wnt signalling, rather than just inhibit it [45,46,47,48]. The
transcription of Wnt/b-catenin target genes was increased by
forming a complex with LEF/TCF (lymphoid enhancer factor/T
cell factor) DNA-binding proteins. We detected the nuclear
translocation of b-catenin to illustrate the interaction of sFRP2
and canonical Wnt signaling. SFRP2 does not alter the nuclear
translocation of b-catenin in MDA-MB-231 cells.
A large number of studies have indicated that Wnt5a
commands a tumor-suppressing effect [13,19,49,50,51,52]. A few
studies have pointed to Wnt5a having an oncogenic role in tumors
arising from a variety of different tissues [11,53,54,55]. Most
studies have involved limited sample sets and a significant number
have not detailed expression at both the RNA and protein levels.
Studies with much larger sample sets will provide the necessary
statistical power to validate the extent of the downregulation of
Wnt5a in cancer. On the other hand, the potential role for
increased Wnt5a expression in malignant melanoma has recently
been outlined as a study established that nuclear beta-catenin
levels are higher in primary tumors than in metastases and that
low expression of nuclear beta-catenin expression in primary
tumors predicts poor survival [56]. Metastatic neuroblasts in a
xenograft model displayed lower Wnt5a expression than the
DDAD-Daam1 (lacking the DAD domain), C-Daam1 (C-terminal of Daam1) and N-Daam1 (N-terminal of Daam1). Residue numbers above domains
denote the domain boundaries. (D) Expression of empty vector, DDAD-Daam1, C-Daam1, or N-Daam1 was verified using total protein from cells and
immunoblotted using anti-GFP antibody. (E) Overexpression of DDAD-Daam1 and C-Daam1 in cells maintained whereas N-Daam1 abolished Wnt5a-
induced cell migration. MDA-MB-231 cells were transiently transfected with empty vector, DDAD-Daam1, C-Daam1 or N-Daam1. Cell migration rate
was determined by wound healing assays, which were allowed to heal for 4 h, in the absence or presence of 500 ng/mL rWnt5a. (F) Efficiency of gene
knockdown was analyzed by RT-PCR (left) and immunoblotting (right) for Daam1. MDA-MB-231 cells were transfected with Daam1 siRNAs or control
(Mock). Total mRNA or protein extracts from MDA-MB-231 transfected with indicated materials were analyzed by RT-PCR and immunoblotting for
Daam1. The same assay was performed with GAPDH as a loading standard. (G) Daam1 siRNA significantly inhibited cell migration. MDA-MB-231 cells
transfected with indicated materials were subjected to a wound healing assay in the absence or presence of 500 ng/mL rWnt5a. Results are
presented as mean 6 s.d. of 5 independent experiments in (E) and (G).
doi:10.1371/journal.pone.0037823.g003
Figure 4. RhoA activation is essential for Wnt5a-induced MDA-MB-231 cell migration. (A, B) RhoA activation was induced by Wnt5a (A)
and blocked by Dvl2 mutants or siRNA (B). Serum-starved MDA-MB-231 cell monolayers were incubated with 500 ng/mL rWnt5a for 0–60 min (A), or
transiently transfected with Dvl2 mutants or siRNA, and then incubated with 500 ng/mL rWnt5a for 30 min (B). Cell lysates were assayed for active
RhoA by pulldown assays. Results are presented as mean 6 s.d. of 3 independent experiments in (A) and (B). (D) Expression of empty vector, WT-
RhoA, V14-RhoA or N19-RhoA was verified using total protein from cells and immunoblotted using anti-GFP antibody. (C, E) Wnt5a-induced cell
migration was abolished by C3 exoenzyme transferase (C) or N19-RhoA, a dominant negative mutant of RhoA (E). MDA-MB-231 cells were
preincubated with Rho inhibitor C3 (10 ng/mL) for 1 h (C), or transiently transfected with empty vector, WT-RhoA, V14-RhoA, or N19-RhoA (E), and
then incubated with 500 ng/mL rWnt5a for 4 h. Cell migration rate was determined by wound healing assay. Results are presented as mean 6 s.d. of
5 independent experiments in (C) and (E).
doi:10.1371/journal.pone.0037823.g004
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37823Figure 5. Daam1 activation is required for Wnt5a-induced RhoA activation. (A) DDAD-Daam1 and C-Daam1 induced while dominant
negative mutant and Daam1 siRNA blocked RhoA activation. MDA-MB-231 cells were transiently transfected with Daam1 mutants or siRNAs, and then
treated with 500 ng/mL rWnt5a for 30 min. Cells were lysed and quantitated for protein and equal amounts of lysates were assayed for active RhoA
by pulldown assays. (B) RhoA did not change the activation of Daam1 with or without Wnt5a treatment. MDA-MB-231 cells were transiently
transfected with WT-RhoA, V14-RhoA and N19-RhoA, and then treated with 500 ng/mL rWnt5a for 30 min. Equal amounts of lysates were assayed for
active Daam1 by pulldown assays. (C) Overexpression of N19-RhoA abolished the Daam1-dependent cell migration. MDA-MB-231 cells were
transiently co-transfected with N19-RhoA and DDAD-Daam1. Cells were subjected to a wound healing assay in the absence or presence of 500 ng/mL
rWnt5a. (D) Expression of empty vector or DDAD-Daam1 was verified using total protein from MCF-7 cells and immunoblotted using anti-GFP
antibody. (E) DDAD-Daam1 induced RhoA activation in MCF-7 cells. MCF-7 cells were transiently transfected with DDAD-Daam1. Cells were lysed and
quantitated for protein and equal amounts of lysates were assayed for active RhoA by pulldown assays. Results are presented as mean 6 s.d. of 3
independent experiments in (A), (B) and (E). (F) MCF-7 cells were stimulated by DDAD-Daam1. MCF-7 cells were transiently transfected with DDAD-
Daam1 or empty vector, and migration was quantified by Boyden chamber assays after 48 h. Values are mean 6 s.d. of 5 independent observations
in (C) and (F).
doi:10.1371/journal.pone.0037823.g005
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effect is disparate between primary tumors and metastases. Most
studies on Wnt5a expression in cancer patient materials focus on
tumorigenesis of primary tumors. Studies of establishing cancer
metastases models in cancer patient materials will bring new
opinion about the clinical situation.
It has been reported that Wnt5a may promote tumor
progression through inducing actin reorganization and increasing
cell motility via activating the PKC and calcium signaling pathway
[10,36]. However, the roles of Wnt5a/PCP signaling are poorly
defined in cancer cells. In this study, we demonstrated that Wnt5a
promotes MDA-MB-231 breast cancer cell migration by activating
Dvl2/Daam1. Dvl phosphorylation, which is the most proximal
signaling event downstream of membrane receptor activation, can
be monitored by a shift in the electrophoretic mobility of
phosphorylated Dvl [24,25,57]. Consistent with these reports, we
found that Wnt5a induced Dvl2 phosphorylation rapidly and
transiently in MDA-MB-231 cells. Blocking Dvl2 signaling by
Dvl2 mutants or siRNA transfection completely abolished Wnt5a-
induced cell migration, indicating that Dvl2 activation participates
in the regulation of the MDA-MB-231 migration. However,
overexpression of Dvl2 did not further promote cell migration,
indicating that endogenous Dvl2 is sufficient for mediating Wnt5a-
induced cell migration. By immunohistochemistry, Dvl1 was
shown to be expressed in 50% of human breast cancers [58].
Wnt5a can also activate Dvl3 by a CK1-dependent mechanism in
dopaminergic cells [59]. Whether Dvl1 and Dvl3, homologs of
Dvl2, induce the migration of breast cancer cells needs to be
further studied.
Daam1 contains multiple regulatory domains. In unstimulated
cells, Daam1 exists in an auto-inhibited state by intramolecular
interaction between its N-terminal GBD and C-terminal DAD
domains [32]. Our results showed that Wnt5a remarkably
activated Daam1 in MDA-MB-231 cells. As previously reported,
overexpression of N-Daam1 inhibits the interaction between
Daam1 and Dvl2 [31]. Interference of Daam1 function via N-
Daam1 overexpression or knockdown of Daam1 expression via
siRNA transfection inhibited RhoA activation and cell migration
by Wnt5a/Dvl2 in MDA-MB-231 cells. But overexpression of C-
Daam1 and DDAD-Daam1, two activated forms of Daam1, did
not further promote cell migration. Furthermore, we tested the
ability of DDAD-Daam1 in stimulating cell migration in a different
breast cancer cell line, MCF-7. Constitutively active DDAD-
Daam1 induced RhoA activation, the formation of stress fibers,
and migration of MCF-7 cells, indicating that Daam1 may be
specifically required for the activation of Dvl2 after Wnt5a
treatment in breast cancer cells.
Wnt signaling activates the small GTPase Rho during Xenopus
embryogenesis and neurite retraction of mouse neuroblastoma
cells [31,60,61]. In our study, specific downregulation of Dvl2/
Figure 6. Daam1 participates in the rearrangement of stress fibers in MDA-MB-231 and MCF-7 cells. (A) N-Daam1 and C3 transferase
disrupted the formation of actin stress fibers in MDA-MB-231 cells. MDA-MB-231 cells were transiently transfected with N-Daam1 or pre-treated with
10 ng/mL C3 transferase for 1 h. MDA-MB-231 cells as well as transiently transfected Daam1 mutants were grown on cover slips, and then incubated
in culture medium containing 500 ng/mL rWnt5a for 4 h. Subsequently, cells were fixed and F-actin organization was analyzed by phalloidin staining.
(C) DDAD-Daam1 enhanced the formation/maintenance of actin stress fibers in MCF-7. MCF-7 cells were transiently transfected with DDAD-Daam1,
and then incubated in culture medium in the absence of Wnt5a. Magnification, 6400. (B, D) The percentage of formation of actin stress fibers was
determined in MDA-MB-231 cells (B) and MCF-7 cells (D), as described in Materials and Methods. The average is shown as mean 6 s.d.
doi:10.1371/journal.pone.0037823.g006
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induced activation of RhoA, and upregulation of Daam1 in
MCF-7 cells induces RhoA activation. Furthermore, blocking
RhoA activity significantly retards Wnt5a-induced stress fiber
formation and cell migration. Similarly, previous studies have
reported that activated RhoA is critical for breast tumor invasion
and metastasis [62,63,64]. Therefore, it is possible that Wnt5a-
induced RhoA activation may participate in the regulation of
MDA-MB-231 and MCF-7 cell migration. Further studies are
needed to decipher whether Wnt5a/PCP signaling products
function in a common Rho pathway or in parallel pathways.
In summary, we presented the first direct evidence that Wnt5a
promotes breast cancer cell migration via Dvl2/Daam1/RhoA.
These findings elucidate a molecular pathway linking Wnt5a
signaling with RhoA in governing cytoskeletal architecture and cell
motility, which may represent a rational molecular target for
manipulating breast cancer.
Supporting Information
Figure S1 Expression of Wnt5a mRNAs and proteins in
human breast cancer cell lines. Total mRNA or protein
extracts from MCF-7 and MDA-MB-231 cells were analyzed by
RT-PCR (top panel) and immunoblotting (bottom panel) for
Wnt5a. The same assay was performed with GAPDH or b-actin as
loading control.
(TIF)
Figure S2 Activity of recombinant Wnt5a (rWnt5a).
rWnt5a was assayed at the indicated doses for electrophoretic
mobility shift by immunoblotting using anti-Wnt5a antibodies.
The rWnt5a migrates as a single band of an approximately
45 kDa in size.
(TIF)
Figure S3 Wnt5a promotes MDA-MB-231 cell migra-
tion. MDA-MB-231 cells were stimulated by 500 ng/mL rWnt5a
for the indicated time. The cell motility rate was measured by
wound healing assay. All values are the mean 6 s.d. of 5
independent observations.
(TIF)
Figure S4 Wnt5a does not appreciably promote MDA-
MB-231 cell growth. Cell proliferation was measured by MTT
assays. The mean optical densities of MDA-MB-231 cells are
shown. MDA-MB-231 cells were cultured on 96-wells in the
absence (Vehicle) or presence of rWnt5a (500 ng/mL). All values
are the mean 6 s.d. of 5 independent observations.
(TIF)
Figure S5 sFRP2 does not alter the nuclear transloca-
tion of b-catenin in MDA-MB-231 cells. MDA-MB-231 cells
were pre-treated with 1000 ng/mL sFRP2 for 1 h, followed by
incubation in the absence or presence of 500 ng/mL rWnt5a for
4 h. Total protein or nucleonic protein extracts from MDA-MB-
231 cells were analyzed by immunoblotting for b-catenin. The
same assay was performed with histone 3 or b-actin as a loading
standard.
(TIF)
Figure S6 The shifted protein of Dvl2 is the phosphor-
ylated form of Dvl2. (A) Immunoblot analysis of Dvl2 in MDA-
MB-231 cell extracts either untreated (Control), treated with
phosphatase, or treated with phosphatase in the presence of
phosphatase inhibitor. The mobility shift upon phosphatase
treatment confirms that the upper Dvl2 band in MDA-MB-231
cells is hyperphosphorylated. (B) Proteins of MDA-MB-231 cells
were immunoprecipitated by anti-Dvl2 antibody, and then were
analyzed by blotting with anti-phosphotyrosine, phosphoserine
and phosphothreonine antibodies.
(TIF)
Figure S7 C3 exoenzyme transferase is a specific Rho
inhibitor. MDA-MB-231 cells were pre-treated with 10 ng/mL
C3 exoenzyme transferase for 1 h, afterwards incubated in the
absence or presence of 500 ng/mL rWnt5a for 30 min. Cells were
lysed and quantitated for protein and equal amounts of lysates
were assayed for active RhoA by pulldown assays.
(TIF)
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